Ummm... guess you didn't watch the R&D day webcast, but that's understandable since you don't own the stock... right?
There are companies that exist to help prepare FDA filings and prep the company executives for an advisory panel. MNKD used one even though they had been through the process before. MNKD had a stellar performance at their panel, turning the tables on the FDA after the FDA came out of the gate swinging hard against approval.
Look at the valuation of some of the PD-1 inhibitor companies. One of the value propositions from the R&D Day webcast was pairing SD101 with a PD-1 inhibitor. Companies in the cancer immunology space are seeing large valuations based on early stage trials. Different companies are also starting to partner to run combo-therapy drug trials in this space.
I think of the pipeline as the raffle ticket that you get for free when you buy shares in DVAX for a bet on Heplisav.
Right. It has nothing to do with Heplisav. But it does have a LOT to do with some of the SD101 trials about to be launched..
Any guess what the capital gains payout might be at EOY? I think last year was about .36 per share... so I'm hoping to effectively three times the normal payout for December.
I'm looking to the fund for monthly income and want to reinvest in the fund, but on a bi-annual basis given the NAV should drop at least for two years as interest rates rise. The effective maturity after hedging is a bit over 4 years for the fund per the Pimco web site. I'm a newbie to bonds so I'm placing a lot of faith in Pimco management to make good choices when purchasing bonds, so reduce the chance of defaults. Pimco web site states 2.6% of fund is E&P.
Also, we're nearing options expiration in Jan 17. MACK always has a lot of volatility around options expiration. It usually ends up near a strike... likely would be 11 or 12.
Seems like same old.. same old... options expire tomorrow and 10 is the battle line.
Avanir acquired at 3.5B... amazing given the following. Makes one only wonder what MACK could be acquired for in three to five years when the pipeline is matures.
Avanir currently sells just one product, Neudexta, a co-formulation of two generic drugs used to treat uncontrollable laughing and crying associated with pseudobulbar affect, a secondary ailment associated with neurological disease or brain injury. This has brought 12-month sales to $104 million, though Avanir has yet to make any money.
JUNO IPO's and hits a 3B market cap and they're just getting started in human trials based on this CEO comment: "We have 10 clinical candidates moving into the clinic next year," says CEO Hans Bishop..."
Maybe you can look at IDRA's market cap to estimate how much this technology might be valued at in early stage development.
Here's a clip from last week's S&P Capital report on DVAX. But it doesn't list what firms are included in their tally:
No.of Ratings %of Total 1Mo. Prior 3Mo. Prior
Buy 4 80 0 4
Buy/Hold 0 0 0 0
Hold 1 20 0 1
WeakHold 0 0 0 0
Sell 0 0 0 0
NoOpinion 0 0 0 0
Total 5 100 0 5
Hopefully he won't start selling PCI. It looks like his latest sale of PDI on 2/2 was less than his previous two.
Ben Graham said the obvious in his book The Intelligent Investor that the time to buy was when an external event, not necessarily related to the underlying fundamentals, drove an asset's price down. So I will be watching PDI to see when Mr. Gross stops selling. PDI has had a huge EOY payout.
STANDARDIZED OPINION CURRENT FIRM OPINION Firm1 / Aggregate Opinion Opinion 1 Year History Investars Smartindex Date Opinion
Columbine Capital Services Inc. (i) Underperform 81.37% 12/01/14 Unfavorable
EVA Dimensions (i) Underperform 85.03% 11/01/14 Underweight
Jefferies Buy 74.79% 11/14/14 Buy
Jefferson Research (i) Sell 73.03% 12/12/14 Sell
McLean Capital Management (i) Neutral 73.93% 01/04/15 Neutral
Thomson Reuters/Verus (i) Neutral 72.96% 01/19/15 Hold
ValuEngine (i) Neutral 105.11% 12/01/14 Hold
William Blair & Company Outperform 73.34% 06/23/14 Outperform
Zacks Investment Research, Inc (i) Neutral 150.48% 10/31/14 Hold
Equity Summary Score (7 Firms†) -- -- 02/14/15 Bearish Thomson Reuters I/B/E/S Estimates (5 Analysts) --
I had disposed of a rental property for a loss, causing my taxable income to drop. TurboTax calculated I was entitled to a $795 tax credit for my ACA policy. That was a pleasant shock.